Speaking at NEALS, Cedar Sinai, and John Hopkins

June 5, 2012 – At the invitation of ALS Association and NEALS, Dr. Smith discussed the scientific basis for an upcoming ALS clinical trial in a webinar entitled: "Determining the Effect of Nuedexta on Speech and Swallowing in ALS: A Multicenter Trial"

February 17, 2012 – Dr. Smith spoke at Cedar-Sinai in Los Angeles.

March 8, 2012 – Dr. Smith spoke at the Packard Conference in John Hopkins.

FDA approves Nuedexta

FDA approves Nuedexta which was discovered at CNS and developed by Avanir pharmaceutical corporation.

2011

November 5, 2011 – Dr. Smith spoke at Neurology grand rounds at Stanford.

June 27-28, 2011 – At the California ALS Summit, held in San Francisco, Dr. Smith gave a talk entitled "The ALS phenotype: lost in translation" and chaired a session dealing with molecular therapy for ALS.

October 1, 2011 – This presentation, titled "Developing therapeutics for amyotrophic lateral sclerosis," to ALS patients/families, sponsored by the ALS association, was made by Dr. Smith in connection with the 2011 California ALS summit.